

CHARTER OF THE TECHNOLOGY COMMITTEE

1 Purpose of the Committee

The purpose of the Technology Committee (the “Committee”) of the Board of Directors (the “Board”) of Ultrablanket Ltd (the “Company”) is to assist the Board in overseeing the role of technology in supporting the Company’s strategy, innovation, clinical development, and operational requirements. This includes reviewing the Company’s technological direction, digital infrastructure, and compliance within a clinical and regulatory framework relevant to Ultrablanket’s mission in maternal health innovation.

2 Composition of the Committee

The Committee shall consist of three or more directors, as determined by the Board from time to time. Members shall be appointed based on relevant expertise and at the discretion of the Board.

The Board shall appoint the Chairperson of the Committee. If the Board does not designate a Chair, the Committee may elect one by majority vote.

A majority vote of the Board shall fill vacancies on the Committee. Members may be removed from the Committee only by a majority vote of the Board.

3 Meetings of the Committee

The Committee shall meet as frequently as needed to fulfil its responsibilities, but no less than once per fiscal quarter. The Committee may invite Company management, technical staff, clinicians, or external advisors to attend meetings and provide relevant information.

Meetings may be held in person or virtually, provided all participants can hear and speak with one another. A majority of Committee members shall constitute a quorum.

The Committee will maintain written minutes and records of its meetings and deliberations.

4 Duties and Responsibilities of the Committee

The Committee’s scope shall remain flexible to allow adaptation to emerging technologies and Company priorities. Its primary duties include:

4.1 Strategic and Operational Oversight

Review, discuss with management, and provide guidance on:

- The Company's core technology strategy, including hardware, software, and AI systems;
- The Company's product development lifecycle and stage-gate processes;
- The product roadmap, from concept through clinical deployment;
- The Company's clinical strategy, including maternal health use cases and clinical trial initiatives;
- Development of clinical evidence, trial design, and execution;
- The Company's regulatory pathway and technology evaluation methodologies;
- Quality Management System (QMS) status and compliance readiness;
- Processes for technology acquisition, partnerships, and investments aligned with strategic growth.

4.2 Capital Investment Review (in coordination with the Audit Committee)

Make recommendations to the Board regarding:

- Capital expenditures and investment requests related to technology;
- The annual technology budget and investment plan;
- The 5-year capital plan for technology development;
- Technology-related risk management and mitigation strategies.

4.3 Risk Coordination

Coordinate with other Board committees to oversee specific technology-related or operational risks.

4.4 Policy Oversight

Review, approve, or recommend technology-related policies for Board approval, including cybersecurity, data governance, and innovation protocols.

4.5 Additional Responsibilities

- Undertake any other responsibilities deemed appropriate by the Committee or requested by the Board.

5 Investigations, Studies, and Outside Advisors

The Committee may conduct or authorise independent investigations or studies into matters within its scope. The Company may also engage external consultants, counsel, or technology advisors as needed, at its expense.